MIL62

Phase 3Small molecule

BBeijing Mabworks Biotech Co., Ltd.

MIL62 is one of 100 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

Membranous NephropathyActive, not recruiting

Systemic Lupus ErythematosusPhase 2

Active, not recruiting

Neuromyelitis OpticaPhase 3

Active, not recruiting

Membranous NephropathyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

328 competitors in Systemic Lupus Erythematosus

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

9 2

Olumiant

Eli Lilly

Phase 3

4 3

Stelara

Johnson & Johnson

Phase 3

3 4

Rinvoq

AbbVie

Phase 3

3 5

Ocrevus

Roche

Phase 3

2 6

Gazyva

Roche

Phase 3

2 7

Intrarosa

Alnylam Pharmaceuticals

Phase 3

1 8

Depo-Provera

Cellcept

Benadryl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Neuromyelitis Optica

NCT05314010

Q4 2028

Phase 3Not yet recruiting

Systemic Lupus Erythematosus

NCT07405970

Clinical

Trials by Indication[1]

Membranous Nephropathy2 trials

A Phase Ⅲ Clinical Study of MIL62 in Primary Membranous Nephropathy

Active, not recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 3·NCT05862233·150 enrolled

A Phase Ib/ Ⅱ Clinical Study of MIL62 in Primary Membranous Nephropathy

Completed·BBeijing Mabworks Biotech Co., Ltd.·Phase 1/2·NCT05398653·94 enrolled

Systemic Lupus Erythematosus2 trials

A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Not yet recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 3·NCT07405970·316 enrolled

A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus

Active, not recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 2·NCT05796206·120 enrolled

Neuromyelitis Optica1 trial

A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Active, not recruiting·BBeijing Mabworks Biotech Co., Ltd.·Phase 3·NCT05314010·102 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for MIL62. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MIL62 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MIL62. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Mabworks Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Mabworks Biotech Co., Ltd.

MIL62

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2028

Trials by Indication[1]

Membranous Nephropathy2 trials

Systemic Lupus Erythematosus2 trials

Neuromyelitis Optica1 trial

References

Drug Info

Quick Facts

Related News